Narcolepsy - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Narcolepsy – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Narcolepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Narcolepsy: Overview
Narcolepsy is a rare long-term brain condition that causes a person to suddenly fall asleep at inappropriate times. The brain is unable to regulate sleeping and waking patterns normally, which can result in: excessive daytime sleepiness – feeling very drowsy throughout the day and finding it difficult to concentrate and stay awake, sleep attacks – falling asleep suddenly and without warning, cataplexy – temporary loss of muscle control resulting in weakness and possible collapse, often in response to emotions such as laughter and anger, sleep paralysis – a temporary inability to move or speak when waking up or falling asleep, excessive dreaming and waking in the night – dreams often come as you fall asleep (hypnogogic hallucinations) or just before or during waking (hypnopompic hallucinations). Narcolepsy is often caused by a lack of the brain chemical hypocretin (also known as orexin), which regulates wakefulness. Narcolepsy is a fairly rare condition. It's difficult to know exactly how many people have narcolepsy because many cases are thought to go unreported. There's currently no cure for narcolepsy, but making changes to improve sleeping habits and taking medicine can help minimize the impact the condition has on your daily life.
'Narcolepsy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Narcolepsy pipeline landscape is provided which includes the disease overview and Narcolepsy treatment guidelines. The assessment part of the report embraces, in depth Narcolepsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Narcolepsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Narcolepsy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Narcolepsy Emerging Drugs
Further product details are provided in the report……..
Narcolepsy: Therapeutic Assessment
This segment of the report provides insights about the different Narcolepsy drugs segregated based on following parameters that define the scope of the report, such as:
Narcolepsy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Narcolepsy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Narcolepsy drugs.
Narcolepsy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Narcolepsy – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Narcolepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Narcolepsy: Overview
Narcolepsy is a rare long-term brain condition that causes a person to suddenly fall asleep at inappropriate times. The brain is unable to regulate sleeping and waking patterns normally, which can result in: excessive daytime sleepiness – feeling very drowsy throughout the day and finding it difficult to concentrate and stay awake, sleep attacks – falling asleep suddenly and without warning, cataplexy – temporary loss of muscle control resulting in weakness and possible collapse, often in response to emotions such as laughter and anger, sleep paralysis – a temporary inability to move or speak when waking up or falling asleep, excessive dreaming and waking in the night – dreams often come as you fall asleep (hypnogogic hallucinations) or just before or during waking (hypnopompic hallucinations). Narcolepsy is often caused by a lack of the brain chemical hypocretin (also known as orexin), which regulates wakefulness. Narcolepsy is a fairly rare condition. It's difficult to know exactly how many people have narcolepsy because many cases are thought to go unreported. There's currently no cure for narcolepsy, but making changes to improve sleeping habits and taking medicine can help minimize the impact the condition has on your daily life.
'Narcolepsy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Narcolepsy pipeline landscape is provided which includes the disease overview and Narcolepsy treatment guidelines. The assessment part of the report embraces, in depth Narcolepsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Narcolepsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Narcolepsy R&D. The therapies under development are focused on novel approaches to treat/improve Narcolepsy.
This segment of the Narcolepsy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Narcolepsy Emerging Drugs
- FT218: Avadel Pharmaceuticals
- AXS-12: Axsome therapeutics
Further product details are provided in the report……..
Narcolepsy: Therapeutic Assessment
This segment of the report provides insights about the different Narcolepsy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Narcolepsy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Narcolepsy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Narcolepsy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Narcolepsy drugs.
Narcolepsy Report Insights
- Narcolepsy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Narcolepsy drugs?
- How many Narcolepsy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Narcolepsy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Narcolepsy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Narcolepsy and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Narcolepsy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Preregistration)
Comparative Analysis
FT218: Avadel Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
TAK-994: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
ADAIR: Vallon Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Narcolepsy Key Companies
Narcolepsy Key Products
Narcolepsy- Unmet Needs
Narcolepsy- Market Drivers and Barriers
Narcolepsy- Future Perspectives and Conclusion
Narcolepsy Analyst Views
Narcolepsy Key Companies
Appendix
Executive Summary
Narcolepsy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Preregistration)
Comparative Analysis
FT218: Avadel Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
TAK-994: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
ADAIR: Vallon Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Narcolepsy Key Companies
Narcolepsy Key Products
Narcolepsy- Unmet Needs
Narcolepsy- Market Drivers and Barriers
Narcolepsy- Future Perspectives and Conclusion
Narcolepsy Analyst Views
Narcolepsy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Narcolepsy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Narcolepsy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Narcolepsy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Narcolepsy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products